Rolf Hoenger – Area Head LatAm, Roche
Rolf Hoenger describes how Roche is driving access and awareness for innovative medicines in Latin America and weighs in on a number of important topics, from regulatory harmonisation in the…
Address: R. Cônego Felipe, 365 – Taquara – Rio de Janeiro – RJ
Tel: (21) 2159-2600
Web: http://www.bago.com.br/web/cgi/cgilua.exe/sys/start.htm?tpl=home
With an innovative profile, Bagó Group is a leader in healthcare in Latin America. It is formed by a pool of solid enterprises, oriented around healthcare and improving quality of life.
Proud to be Latin American, the group was founded in 1934 in Argentina, and today is one of the most significant in the world pharmaceutical market. With an outstanding presence in Latin America and extending its roots over the world, it counts on over 6500 employees that share the same values of innovation and the same ideals of growth.
Laboratórios Bagó was established in Brazil in 2002, with the aim of working in the pharmaceutical industry as a tool for building a strong laboratory, and now counts a multidisciplinary team composed by over 180 professionals.
It is an intellectual leader, a reference in the Marketing business and has worked with Merck, Glaxo and Roche Laboratories.
Hydrophilic Array, Trifamox IBL, Magnesium Valproate, Alprazolam Sublingual, Talniflumate
Rolf Hoenger describes how Roche is driving access and awareness for innovative medicines in Latin America and weighs in on a number of important topics, from regulatory harmonisation in the…
After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV…
Although Brazil is one of the world’s top pharma markets, with the highest market value in Latin America, and has made major strides towards universal healthcare, the country continues to…
Novo Nordisk’s Latin America lead Allan Finkel outlines the “alarming” burden of diabetes and obesity in his region, the progress that has been made via national campaigns against diabetes, and…
GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance…
The latest from Brazilian Pharma, including the approval of home grown cannabis for medical use, Cellera Farma’s partnership with Ferring, a considerable increase in demand for oncology drugs, and a…
The latest from the healthcare industry in Latin America, including an alarming OECD report about the decline of well-being in the region due to Covid-19, Bayer’s USD 350 million investment…
The latest news from Brazil, including Pfizer’s plans to vaccinate the entire Brazilian city of Toledo, what the US can learn from Brazil’s successful vaccine campaign, and a new deal…
The latest news from Brazilian pharma, including an investigation into the country’s deal with Indian lab Bharat Biotech to purchase COVID-19 vaccines; the IP and regulatory challenges around personalised medicine…
Founded in 1950, EMS is one of the top two domestic pharma companies in Brazil. As a key player in the largest and most populous nation in Latin America, the…
The Brazilian pharma market outperformed the Latin American average in Q1 of 2020 with a growth of 8.2 percent in real terms (inflation adjusted), according to IQVIA. Its size reached…
Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known…
See our Cookie Privacy Policy Here
